Ipsen To Buy Five Products for $88M From Rival Sanofi

Deal spurred by requirements from the European Commission to sell assets from a previous deal with Boehringer Ingelheim.
Feb. 14, 2017

Ipsen has reached an agreement to buy five consumer healthcare products from French rival Sanofi for approximately $88 million.

The deal was spurred by requirements from the European Commission to sell certain assets from a previous deal between Sanofi and the German Boehringer Ingelheim.

Ipsen are acquiring Buscopan, Suppositoria Glycerini, Mucothiol, Mucodyne, and Prontalgine, a pain treatment that has grown at double-digit rates over the last four years.

In January, Ipsen bought Merrimack pancreatic cancer drug ONIVYDE.

Read the Reuters report

Sign up for Pharma Manufacturing Newsletters
Get the latest news and updates